PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/170961

Please be advised that this information was generated on 2017-09-01 and may be subject to change.
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

Ingrid M E Desar1
Anastasia Constantinidou2
Suzanne E J Kaal1
Robin L Jones2
Winette T A van der Graaf1,2

1Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; 2The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK

Abstract: Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy.

Keywords: soft-tissue sarcoma, trabectedin, chemotherapy

Introduction
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. STS account for approximately 1% of adult cancers, with an annual incidence of 5 per 100,000 inhabitants.1 Although STS can arise anywhere in the body, the majority occur in the limb or limb girdle (60%) or within the abdomen (retroperitoneal and intraperitoneal, 20%).2 Over 50 different subtypes of STS have been identified in the latest World Health Organization classification of tumors of soft tissue and bone based on clinical insights, histopathology, and molecular biology.3 The most common subtypes, together accounting for about three-quarters of all STS, are undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, myxofibrosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors.3 Molecular diagnostics are increasingly used to identify histological subtypes of STS.4 The etiology of most STS is unknown, but in a minority of STS patients an association exists with irradiation,5,6 chronic lymphangioedema,7 viral infections (eg, HHV-8 in Kaposi sarcoma),8 and known genetic susceptibility (eg, malignant peripheral nerve sheath tumors in neurofibromatosis).9 About 10% of patients have detectable metastases (most common in the lungs) at diagnosis of the primary tumor and, depending on the grade, overall, one-third to half of patients with STS die due to tumor-related diseases.3

In this review, we focus on the currently available systemic treatment strategies for advanced or metastatic STS in adults, with an emphasis on trabectedin.

Current standard of care for advanced STS: in a glance
Localized STS have traditionally been managed by wide excisional surgery with or without radiotherapy. The use of chemotherapy or targeted therapy has mostly been
reserved for advanced disease, aiming to achieve disease palliation and control. The profound heterogeneity of STS subtypes complicates the conduct and interpretation of clinical trials. Within the group of STS, subtypes have been identified as less or more sensitive to systemic therapy, but most studies recruit all histological subtypes and are not powered for this kind of subgroup analyses. Therefore, most STS subtypes are treated in the same way. Selected sarcomas, including gastrointestinal stromal tumors (GIST), Ewing family of tumors, and embryonal or alveolar rhabdomyosarcomas, are exceptions that are effectively treated with specific systemic therapies and are excluded from this review.10

Cytotoxic chemotherapy is the mainstay of therapy for advanced or metastatic STS (Table 1). Targeted therapy, in particular pazopanib,11 currently has a modest role but is under extensive investigation and is likely to gain further importance in advanced STS. A number of early trials utilizing immunotherapy have been initiated. A recent review summarizes gold standard and novel therapies for advanced STS.12,13

First-line systemic therapy

Doxorubicin or combination of doxorubicin plus ifosfamide

The anthracycline doxorubicin is considered to be the standard first-line systemic therapy for advanced STS.10,12 Doxorubicin is administered intravenously (IV) at a dose of 60–75 mg/m² every 3 weeks. This drug has dose-limiting cumulative cardiotoxicity. Response rates for single-agent treatment with doxorubicin vary between 16% and 27%. Median overall survival (OS) varies between 7.7 and 12 months.14 In 2003, a Cochrane review based on eight randomized controlled trials compared doxorubicin as single agent to doxorubicin-based combination therapy (of which two trials were with doxorubicin and ifosfamide). For the combination schedules, a response rate varying between 14% and 34% was found with a median OS of 7.3–12.7 months. It was concluded that doxorubicin-based combinations add a marginal increase in response rate, at the expense of increased toxic effects, but no significant improvement in OS.14 In 2014, the EORTC STSBG 62012 study compared single-agent doxorubicin to the combination of doxorubicin and ifosfamide with comparable results: a response rate of 13.6% vs 26.5%, median progression-free survival (PFS) of 4.6 vs 7.4 months, and no significant difference in median OS (12.8 vs 14.3 months) but significantly more adverse events in the combination arm.15 Therefore, the combination of doxorubicin and ifosfamide is recommended when a volume response is the primary aim, eg, in cases of symptomatic disease (pain and dysfunction) or induction treatment before radical surgery.

A Phase III trial randomizing patients with advanced/metastatic STS to receive first-line therapy with either doxorubicin + palifosfamide or doxorubicin + placebo reported no difference in PFS and OS between the two arms. Furthermore, another Phase III trial randomizing patients to receive doxorubicin + evosofamide or single-agent doxorubicin also reported no difference in outcome (NCT01440088). Therefore, on the basis of the results of these Phase III trials, single-agent doxorubicin is generally regarded as standard first-line therapy for patients with advanced/metastatic STS.

Currently, the combination of doxorubicin and the platelet-derived growth factor receptor alpha antibody olaratumab is under investigation as first-line treatment for all STS subtypes. In the Phase II study, up to eight cycles of

| Table 1 Systemic therapies for advanced or metastatic STS, other than trabectedin |
|-----------------|----------------|-----------------|-----------------|-----------------|
| Drug            | Reference      | ORR (%)         | mPFS (months)   | mOS (months)    | Most commonly reported adverse events |
| Doxorubicin     | 14             | 16–27           | 4.6             | 7.7–12.8        | Leucopenia, neutropenia               |
| Doxorubicin + ifosfamide | 15 | 14–34           | 7.4             | 7.3–14.3        | Leucopenia, neutropenia, febrile neutropenia, anemia, thrombocytopenia, nausea, vomiting, encephalopathy |
| Gemcitabine + docetaxel | 17–21 | 5–52           | 6–6.2           | 16–26.9         | Anemia, fatigue, alopecia, thrombocytopenia, dyspnea, neutropenia |
| Taxanesa       | 22–27          | 7–89            | –               | 7–9.5           | Anemia, neutropenia, fatigue, neuropathy |
| Cyclophosphamide + prednisone | 29 | 26.9          | 6.8             | –               | Lymphopenia, anemia, thrombocytopenia |
| Ifosfamide      | 30–34          | 20–25           | –               | 12              | Fatigue, nausea, vomiting             |
| Gemcitabine     | 35–39          | 3.2–27          | 1.5–6.3         | 7.2–20          | Hematologic toxicities, increased ALT levels, myalgia, rash |
| Dacarbazine     | 40–44          | 4–18            | 2               | 8.2–11.5        | Hematologic toxicities, fatigue, nausea vomiting, stomatitis |
| Eribulinb      | 44             | 4               | 2.6             | 13.5            | Fatigue, nausea, alopecia, constipation, leukopenia, neutropenia, anemia |
| Pazopanib      | 11             | 6               | 4.6             | 12.5            | Fatigue, diarrhea, nausea, weight loss, hypertension |

Notes: 'aIn (mainly uterine) leiomyosarcoma, ‘bIn angiosarcoma, ‘cIn leiomyosarcoma and liposarcoma.
Abbreviations: STS, soft tissue sarcoma; ORR, objective response rate; mPFS, median progression free survival; mOS, median overall survival; ALT, alanine aminotransferase.
doxorubicin (75 mg/m² every 3 weeks) were combined with olaratumab 15 mg/kg IV day 1 and 8 for every 3 weeks. Interim OS analysis showed an impressive difference of 25.0 vs 14.7 months (hazard ratio [HR] = 0.44, P = 0.0005) in favor of the combination therapy. There was no significant difference in objective response rate (ORR), 18.8% and 12.3%, respectively, for the combination and single-agent arms. The Phase III study has nearly completed enrollment.

**Gemcitabine–docetaxel**

In patients with metastatic leiomyosarcoma, the combination of fixed-dose gemcitabine (900 mg/m² IV day 1 and 8q21 days) with docetaxel (100 mg/m² IV day 8q21 days) is used based on three Phase II studies in patients with advanced or metastatic leiomyosarcoma. For patients with uterine leiomyosarcoma, response rates ranged between 24% and 52%. However, the best response rate in patients with nonuterine leiomyosarcoma was only 5%. Recently, a Phase III study was published comparing gemcitabine and docetaxel plus bevacizumab vs gemcitabine and docetaxel plus placebo as first line in 107 patients with uterine leiomyosarcoma. No differences between the two study arms were reported. Response rates were 35.8% and 31.5%, median PFS was 4.2 and 6.2 months, and median OS was 23.3 and 26.9 months for the placebo vs the bevacizumab arm, respectively.

The results of the UK GeDDIS trial have been presented at the ASCO annual meeting in 2015. In this Phase III trial, 257 patients with STS were randomized between doxorubicin 75 mg/m² q21 days or the combination of gemcitabine 650 mg/m² day 1 and 8q21 days and docetaxel 75 mg/m² every 21 days. No significant difference in median PFS (23 and 24 weeks, respectively) or median OS (71 and 63 weeks, respectively) was reported. Subgroup analysis showed no benefit for patients with leiomyosarcoma treated with gemcitabine–docetaxel compared to other histological subtypes. The full paper is not yet published. A Phase II trial is currently recruiting and randomizing patients with advanced/metastatic leiomyosarcoma to trabectedin or gemcitabine–docetaxel (NCT02249702).

**Taxanes**

In patients with advanced or metastatic angiosarcoma, taxanes have shown efficacy, based on the results of several retrospective studies and Phase II trials. These include paclitaxel in a weekly or 3-weekly schedule and docetaxel in a 3-weekly schedule. Response rates vary between 7% and 89% (best response rates in facial and scalp angiosarcoma) and median OS between 7 and 9.5 months. A recent Phase II study combining paclitaxel with bevacizumab showed no benefit for the combination.

**Metronomic cyclophosphamide and prednisolone**

In elderly frail patients with advanced or metastatic STS, unfit for standard first-line therapy with doxorubicin or combination of doxorubicin and ifosfamide, the combination of oral cyclophosphamide 100 mg twice daily and prednisolone 20 mg daily from day 1 to 7 every 14 days has been reported to show benefit. In a retrospective study performed at the Institut Gustave Roussy, the response rate was 26.9%, disease control rate was 69.2%, and median PFS was 6.8 months. Further studies are required to define the precise role of this schedule in patients with advanced/metastatic STS. Lymphopenia, anemia, and thrombocytopenia were the most common reported adverse events.

**Beyond first line of systemic therapy**

After failure to first-line therapy, several systemic options are available, and the selection of a specific schedule is made on the basis of individual patient-based considerations, including expected toxicity, tumor burden, and histological subtype. In a recent review by the Royal Marsden Hospital Sarcoma Unit, a proposal for sequencing therapy was published.

**Ifosfamide**

As a monotherapy, the alkylating agent ifosfamide has activity varying from 4.8% to 62.5%. In subsequent studies, ifosfamide consistently yielded response rates of approximately 20%–25% in the metastatic setting, with a median OS duration of 1 year, results comparable to those obtained with doxorubicin. Several doses and schedules of ifosfamide have been investigated in STS patients. There is a clear dose–response relationship with this agent, and consequently higher doses up to 12–18 g/m² and prolonged dosing schedules have been studied. Dose-limiting toxicities are bone marrow suppression, hemorrhagic cystitis, and encephalopathy. A randomized trial comparing two different schedules of ifosfamide 9 g/m² to doxorubicin demonstrated no advantage for ifosfamide over doxorubicin. In a large retrospective analysis of the EORTC Soft Tissue and Bone Sarcoma Group, synovial sarcomas showed a higher response rate on ifosfamide-containing regimens than on doxorubicin. Prolonged infusion of ifosfamide (1 g/m²/d for 14 days in cycles of 28 days) has retrospectively been reported in 35 STS patients with encouraging results. Partial response was seen in 20% of the patients, and stable disease in another 29%. In the subgroup with dedifferentiated liposarcoma...
(n=22), the partial response rate was 22.7% and stable disease in 31.8%. Median PFS and OS were 4.2 and 11.2 months, respectively. The most common toxicities were fatigue, nausea, and vomiting.34

**Gemcitabine**

Gemcitabine is an antimetabolite of pyrimidine. In unselected STS, a weekly gemcitabine schedule with 1,000–1,250 mg/m² administered in 30 minutes with a pause week every 3–4 weeks is most frequently used. In six gemcitabine monotherapy Phase II studies with pretreated unselected STS, ORRs of 3.2%–27% were reported. Median PFS varied between 1.5 and 6.3 months and median OS between 7.2 and 20 months.19,35–38 Most frequently occurring toxicities are hematologic toxicities, increased alanine aminotransferase levels, myalgia, and rash.

**Dacarbazine**

Dacarbazine is an alkylating agent and is administered 1.2 g/m² every 3 weeks IV as a monotherapy. In three second-line Phase II trials, the response rate was 4%–18%, with a median PFS of 2 months and a median OS of 8.2 months.40–42 Most reported toxicities are hematologic toxicities, nausea, vomiting, flulike symptoms, and diarrhea.40

Recently, dacarbazine was the standard arm in comparison to trabectedin in a large Phase III study for patients with metastatic liposarcoma or leiomyosarcomas after failure of conventional chemotherapy. The dacarbazine group had a median PFS of 1.5 months and a median OS of 12.9 months.43 This trial is discussed in more detail in the “Trabectedin” section.

Dacarbazine (500 mg/m² q2weeks) has been combined with gemcitabine (1,800 mg/m² q2weeks) in two Phase II trials, of which one randomized against single-agent dacarbazine.41,42 For the combination, median PFS was 4.2 months and median OS 16.8 months in the randomized Phase II trial. Despite hematologic toxicities, fatigue, nausea, vomiting, and stomatitis were the most reported adverse events.

**Eribulin**

Recently, the results of a Phase III trial comparing eribulin to dacarbazine were published.44 A total of 452 patients with intermediate- or high-grade advanced liposarcoma or leiomyosarcoma who had received at least two previous systemic regimens for advanced disease (including an anthracycline) were randomized 1:1 to eribulin mesilate (1.4 mg/m² IV on days 1 and 8) or dacarbazine (850–1,200 mg/m² IV on day 1) every 21 days until disease progression. OS was significantly improved in patients assigned to eribulin compared with those assigned to dacarbazine (median OS =13.5 vs 11.5 months; HR =0.77). This OS benefit was only seen in liposarcoma patients (median OS =15.6 vs 8.4 months, respectively) and not in those with leiomyosarcoma (12.7 vs 13.0 months). However, this study was not powered for such subgroup analyses. Median PFS was similar in both treatment groups: 2.6 months. Most reported adverse events for eribulin were fatigue, nausea, alopecia, constipation, leukopenia, neutropenia, and anemia.

**Pazopanib**

Currently, the tyrosine kinase inhibitor pazopanib is the only targeted therapy approved for advanced or metastatic nonadipocytic, non-GIST STS after failure of standard chemotherapy. Pazopanib has activity against VEGFR1–2, PDGFR A–B, and KIT. In the PALETTE study,11 369 patients were randomized 2:1 to receive pazopanib 800 mg once daily orally or placebo. Median PFS was significantly longer in the pazopanib arm, 4.6 vs 1.6 months (HR =0.31, 95% CI =0.24–0.40, P<0.0001), but no significant difference in median OS was found (12.5 vs 10.7 months, HR =0.85, 95% CI =0.67–1.11, P=0.25). Partial responses were seen in 6% of the patients on pazopanib, and another 67% had stable disease as best response. Most reported adverse events were fatigue, diarrhea, nausea, weight loss, and hypertension. Quality of life did not differ between both arms but was only monitored during the first 12 weeks of treatment.

**Trabectedin: pharmacology, mode of action, pharmacokinetics, toxicity, and registration**

Trabectedin (Yondelis®, Janssen Biotech, Inc, Horsham, PA, USA) is a tetrahydroisoquinoline, which was originally isolated from the Caribbean tunicate Ecteinascida turbinata and is currently produced synthetically.45

Trabectedin has several modes of action. Unlike classical alkylating chemotherapeutic drugs, which bind to the major DNA groove, trabectedin binds to specific selected triplets of the DNA minor groove. This results in a distortion of the double helix structure and causes double-strand breaks, leading to tumor cell apoptosis. Part of the molecule protrudes out of the DNA and interacts with proteins at the site of the adduct, such as XPG and RNA polymerase II (Pol II). This results in inhibition of transactivated transcription in a nucleotide excision repair-dependent manner.46,47 This impact on transcription is especially of interest in translocation-related sarcomas, such as myxoid liposarcoma.
and Ewing sarcoma. In myxoid liposarcomas, the presence of t(12;16) or t(12;22) translocations leads to FUS-CHOP or EWS-CHOP fusion proteins. Trabectedin displaces these fusion proteins from its target promoters, resulting in the differentiation of myxoid liposarcoma cells into normal adipocytes.\textsuperscript{48} In Ewing sarcoma, the translocation t(11;22) results in an oncogenic fusion gene \textit{EWS-FLI1}, a crucial driver for the oncogenic transformation and survival of Ewing sarcoma cells. Trabectedin has a specific inhibitory effect on the oncogenic transformation and survival of Ewing sarcoma in an oncogenic fusion gene, a crucial driver for the oncogenic transformation and survival of Ewing sarcoma cells. Trabectedin induces rapid apoptosis exclusively in mononuclear phagocytes (macrophages and monocytes), with a subsequent strong decrease in the production of several cytokines and chemokines such as IL-6, CCL2, CXCL8, Angiopoietin 2, and VEGF. This results not only in diminished tumor growth, but also in inhibition of tumor angiogenesis and modulation of stroma-mediated resistance to therapy.\textsuperscript{46}

Trabectedin is administered IV. The approved schedule is a 24-hour supply using a central venous catheter. Shorter schedules (eg, 1 or 3 hours) have been tested, but have not shown benefit.\textsuperscript{51–53} Trabectedin has a high volume of distribution since 94%–98% of trabectedin within the plasma is bound to albumin. Trabectedin is metabolized by the cytochrome P450 system, especially CYP3A4. Less than 1% is eliminated unchanged in the urine. The terminal half-life time is long, approximately 180 hours. A population pharmacokinetic analysis indicated that the plasma clearance of trabectedin is not influenced by age, sex, total body weight, or body surface area. There are no data available in patients with a creatinine clearance below 30 mL/min. The mode of metabolism and elimination suggest no significant impact of decreased renal function. The impact of hepatic failure on trabectedin pharmacokinetics is unclear, but because of its toxicity profile with (sometimes) highly elevated hepatic enzyme levels, caution is warranted.\textsuperscript{54}

The most common adverse events of trabectedin are neutropenia (50% ≥ grade 3), thrombocytopenia (13% ≥ grade 3), anemia (13% ≥ grade 3), anorexia, nausea, vomiting, diarrhea or constipation, fatigue, asthenia, hyperbilirubinaemia (1% grade 3), and elevated ALT (41% ≥ grade 3) or aspartate aminotransferase (AST) (51% ≥ grade 3), or creatinine phosphokinase (4% ≥ grade 3).\textsuperscript{54} Trabectedin is administered until progressive disease or intolerability. Recently, a randomized Phase II study was reported, which compared interruption of trabectedin after six cycles in patients with responding or stable disease to continuation of trabectedin and found a worse PFS in the discontinuation group (PFS at 6 months after randomization 23.1% vs 51.9%, respectively).\textsuperscript{55}

In Europe, trabectedin is approved by the European Medicines Agency for advanced STS after failure of anthracyclines. In the United States, the US Food and Drug Administration approved trabectedin in November 2015 for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma previously treated with an anthracycline-containing regimen, on the basis of the randomized trial comparing dacarbazine to trabectedin.\textsuperscript{43} Furthermore, it is registered for relapsed ovarian cancer in combination with pegylated liposomal doxorubicin.

**Trabectedin in sarcoma: efficacy**

**Efficacy in first line**

In three Phase II/IIb trabectedin studies in chemotherapy naïve unselected STS patients, response rates were moderate (10%–17.1%) and median PFS was short (1.6–5.8 months). Median OS data are not yet available (Table 2).\textsuperscript{52,56,57} In the TRUSTS study, a direct comparison with doxorubicin was made.\textsuperscript{52} There were no significant differences in ORR, median PFS, or median OS. As already mentioned, response rates for single-agent treatment with doxorubicin vary between 16% and 27%. Median OS varies between 7.7 and 12 months.\textsuperscript{14} Taken together, in unselected advanced or metastatic STS, there is no evidence to choose trabectedin above the regular standard first-line therapy with doxorubicin.

A Phase III trial in 121 translocation-related sarcomas did not show any superiority for either doxorubicin or trabectedin in a direct comparison between those two drugs.\textsuperscript{58} Again, ORRs were numerically higher in doxorubicin-treated patients (27% vs 5.9%), although this was not statistically significant.

**Beyond first-line systemic treatment**

In four Phase II trials in unselected, pretreated, STS patients, the reported response rates were 2.8%–8%, median PFS was 1.7–3.5 months, and median OS was 9.2–12.8 months for trabectedin.\textsuperscript{59–62} A randomized Phase II study comparing trabectedin to best supportive care in translocation-related sarcomas showed a significantly better response rate (8% vs 0%), longer median PFS (5.6 vs 0.9 months, HR = 0.07), and longer median OS (not reached vs 8 months, HR = 0.42).\textsuperscript{63} A large Phase II study in 270 patients with liposarcoma or leiomyosarcoma compared two different trabectedin schedules. Again, low
### Table 2 Results of trabectedin trials in STS patients

<table>
<thead>
<tr>
<th>Reference</th>
<th>Phase</th>
<th>Design</th>
<th>n</th>
<th>RR (%)</th>
<th>TTP (months)</th>
<th>PFS (months)</th>
<th>OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>70</td>
<td>I</td>
<td>Japanese STS pts, after failure of anthracyclines, dose escalation, MTD 1.2 mg/m² q21 day</td>
<td>15</td>
<td>20</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>56</td>
<td>II</td>
<td>TRB 1.5 mg/m² q21h 24 h</td>
<td>35</td>
<td>17.1</td>
<td>–</td>
<td>1.6</td>
<td>15.8</td>
</tr>
<tr>
<td>57</td>
<td>II</td>
<td>TRB 1.5 mg/m² q21d, u-LMS, first-line STS</td>
<td>20</td>
<td>10</td>
<td>4.5</td>
<td>5.8</td>
<td>&gt;26.1 (median not reached)</td>
</tr>
<tr>
<td>52</td>
<td>Iib</td>
<td>Doxo vs TRB 3 vs TRB 24 hours first-line STS</td>
<td>133</td>
<td>Doxo: 25.6 TRB 3 hours: 14.8 TRB 24 hours: 7.6 NS</td>
<td>–</td>
<td>Doxo: 5.5 TRB 3 hours: 2.8 TRB 24 hours: 3.1 NS</td>
<td>TRB 24 hours vs doxo HR 0.94 NS TRB 3 hours vs doxo HR 1.30 NS (preliminary analysis)</td>
</tr>
<tr>
<td>59</td>
<td>II</td>
<td>TRB 1.5 mg/m² q21d pretreated STS</td>
<td>99</td>
<td>8</td>
<td>–</td>
<td>3.5</td>
<td>9.2</td>
</tr>
<tr>
<td>62</td>
<td>II</td>
<td>TRB 1.5 mg/m² q21d pretreated STS</td>
<td>36</td>
<td>8</td>
<td>–</td>
<td>1.7</td>
<td>12.1</td>
</tr>
<tr>
<td>60</td>
<td>II</td>
<td>TRB 1.5 mg/m² q21d pretreated STS</td>
<td>54</td>
<td>4</td>
<td>–</td>
<td>1.9</td>
<td>12.8</td>
</tr>
<tr>
<td>61</td>
<td>II</td>
<td>TRB 1.3–1.65 mg/m² 3hq21d + dexamethasone or placebo, pretreated STS</td>
<td>35</td>
<td>2.8</td>
<td>–</td>
<td>2.1</td>
<td>10.2</td>
</tr>
<tr>
<td>51</td>
<td>II</td>
<td>TRB 1.5 mg/m² q3weeks vs TRB 0.58 mg/m² 3 hours day 1, 8, 15 every 4 weeks. L-sarcoma, after failure anthracyclines and ifosfamide</td>
<td>270</td>
<td>5.6 vs 1.6</td>
<td>3.7 vs 2.3, HR =0.73, P=0.03</td>
<td>3.3 vs 2.3, HR =0.76, P=0.04</td>
<td>13.9 vs 11.8, HR =0.84, P=0.19</td>
</tr>
<tr>
<td>63</td>
<td>II</td>
<td>TRB 1.2 mg/m² q3wk vs best supportive care in translocation-related sarcoma after standard chemotherapy</td>
<td>76</td>
<td>8 vs 0</td>
<td>–</td>
<td>5.6 vs 0.9, HR =0.07, P&lt;0.0001</td>
<td>Not reached vs 8.0, HR =0.42, P=0.04</td>
</tr>
<tr>
<td>68</td>
<td>II</td>
<td>TRB 1.5 mg/m² q21d neoadjuvant myxoid liposarcoma</td>
<td>23</td>
<td>24</td>
<td>2 patients pCR</td>
<td>5.9 TRB vs 27 doxo</td>
<td>HR 0.85 NS (preliminary analysis)</td>
</tr>
<tr>
<td>58</td>
<td>III</td>
<td>TRB 1.5 mg/m² q21 vs doxorubicin in translocation-related sarcoma</td>
<td>121</td>
<td>5.9 TRB vs 27 doxo</td>
<td>–</td>
<td>HR 0.85 NS</td>
<td>HR 0.77 NS (preliminary analysis)</td>
</tr>
<tr>
<td>43</td>
<td>III</td>
<td>TRB 1.5 mg/m² q21 vs dacarbazine in L-sarcomas after anthracycline and one additional chemotherapy</td>
<td>518</td>
<td>9.9 vs 6.9</td>
<td>–</td>
<td>4.2 vs1.5, HR =0.52, P&lt;0.0001</td>
<td>12.9 vs 12.4, HR =0.87, P=0.37</td>
</tr>
<tr>
<td>64</td>
<td>IVb</td>
<td>TRB 1.5 mg/m² q3wk. All STS after standard chemotherapy</td>
<td>807 evaluable out of 1,895. 476/807 L-sarcoma</td>
<td>All 5.9 L 6.9</td>
<td>2.3</td>
<td>–</td>
<td>All 11.9 L-sarcoma 16.2</td>
</tr>
</tbody>
</table>

Note: bWorldwide expanded access program study.

**Abbreviations:** IA, interim analysis; L-sarcoma, liposarcoma and leiomyosarcoma; RR, response rate; TTP, time to progression; PFS, progression free survival; OS, overall survival; STS, soft tissue sarcoma; TRB, trabectedine; MTD, maximum tolerated dose; q, every; doxo, doxorubicin; HR, hazard ratio; NS, not significant; pCR, pathological complete response; NA, not applicable.
response rates (5.6%) and short median PFS (3.3 months) with a median OS of 13.9 months were found in the now regular dosing arm of 1.5 mg/m² every 3 weeks.\(^{51}\)

Recently, the results of a Phase III trial with trabectedin vs dacarbazine in patients with L-sarcomas progressive after anthracyclines and one other prior chemotherapy were reported.\(^{41}\) A total of 518 patients were enrolled and randomly assigned to either trabectedin (n=345) or dacarbazine (n=173). Median PFS for trabectedin vs dacarbazine was 4.2 vs 1.5 months, HR = 0.55, \(P<0.001\). In the predefined subanalyses, all subgroups benefited from trabectedin, although the benefit was not statistically significant in all these subgroups. The interim analysis of OS (64% censored) demonstrated a nonsignificant 13% reduction in risk of death in the trabectedin arm compared with dacarbazine (median OS for trabectedin vs dacarbazine, 12.4 vs 12.9 months, HR = 0.87, \(P=0.37\)).

In conclusion, only a modest difference in the efficacy of trabectedin in translocation-related sarcomas compared to unselected STS (also including translocation-related STS) has been observed (both in the first and subsequent lines of therapy). More convincing results for translocation-related sarcomas compared to unselected STS were found in the expanded access trial.\(^{64}\) In this trial, STS patients progressive after standard chemotherapy were treated with trabectedin 1.5 mg/m² every 3 weeks. Four hundred and seventy six of 807 patients was 5.9% (95% CI = 4.4–7.8). For patients with L-sarcomas (n=476), the ORR was 6.9% (95% CI = 4.8–9.6), whereas patients classified as non-L-sarcoma (n=302) had an ORR of 4.0% (95% CI = 2.1–6.8). A total of 258 patients with L-sarcoma experienced CR, PR, or stable disease, a clinical benefit rate of 54%, compared with 114 patients with non-L-sarcoma (the clinical benefit rate of 38%). Nine hundred and three patients were evaluable for OS. In the total group, median OS was 11.9 months; in the group of patients with L-sarcomas (n=509) median OS was 16.2 months (95% CI = 14.1–19.5), and in the non-L-sarcoma patients median OS was 8.4 months (95% CI = 7.1–10.7). Patients with liposarcoma (n=184) had a 2 months longer median survival than those with leiomyosarcoma (n=325; 18.1 vs 16.2 months).\(^{64}\)

### Combinations of trabectedin in STS

The combination of trabectedin and doxorubicin has been studied in two Phase I trials and one Phase II trial (Table 3).\(^{65–67}\) Both Phase I studies in unselected STS patients concluded the recommended Phase II dose of doxorubicin as 60 mg/m² every 3 weeks. For trabectedin, the recommended dose in one study\(^{65}\) was 0.7 g/m² in 3 hours every 3 weeks, and in the other study 1.1 g/m² in 3 hours every 3 weeks.\(^{66}\) Dose-limiting toxicities were thrombocytopenia, (febrile) neutropenia, and asthenia. The difference in recommended trabectedin dose seems to be explained by the difference in accepted pretreatments. Patients in the study assessing the 0.7 g/m² dose\(^{65}\) were heavily pretreated, while in the 1.1 g/m² study\(^{66}\) 0–1 prior treatments were allowed and, therefore, only seven out 41 patients had received prior systemic therapy. Other more frequently occurring toxicities were increased ALT/AST, nausea, vomiting, and stomatitis. The ORR in the two Phase I trials was 12% – 17.9%, which is numerically higher than the response rate of single-agent trabectedin but lower

<table>
<thead>
<tr>
<th>Reference</th>
<th>Phase</th>
<th>Design</th>
<th>n</th>
<th>RR (%)</th>
<th>TTP (months)</th>
<th>PFS (months)</th>
<th>OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>69</td>
<td>I</td>
<td>TRB 0.9 mg/m² d1 and gemcitabine 700 mg/m² d1-8q21 days</td>
<td>5*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>I</td>
<td>RD TRB 0.7 mg/m² 3 hours and doxorubicin 60 mg/m² q21, pretreated STS and breast cancer</td>
<td>29 STS</td>
<td>17.9</td>
<td>12.5</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>66</td>
<td>I</td>
<td>MTD TRB 1.1 mg/m² 3 hours and doxorubicin 60 mg/m² q21 STS 0–1 prior chemotherapy other than anthracyclines</td>
<td>41</td>
<td>12</td>
<td>9.2</td>
<td>Not reached, &gt;14.8</td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>II</td>
<td>TRB 1.1 mg/m² in 3 hours and doxorubicin 60 mg/m² q21 day. First line, u-LMS, and STS-LMS</td>
<td>109 u-LMS 59.6 STS-LMS 39.4</td>
<td>u-LMS 6.6 STS-LMS 12.5</td>
<td>u-LMS 8.2 STS-LMS 12.9</td>
<td>u-LMS 20.2 STS-LMS 34.5 (median follow up 9.9 and 14.5)</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** *Not tolerated; 4/5 patients DLT.

**Abbreviations:** u-LMS, uterine LMS; RD, recommended dose; MTD, maximum tolerated dose; TRB, trabectidin; LMS, leiomyosarcoma; STS, soft-tissue sarcoma; RR, response rate; TTP, time to progression; PFS, progression free survival; OS, overall survival; DLT, dose limiting toxicity; q, every; NA, not applicable.
than the response rate of single-agent doxorubicin when administered as first-line therapy.

In a French Phase II trial, previously untreated patients with advanced or metastatic uterine leiomyosarcoma (u-LMS, n=47) or soft-tissue leiomyosarcoma (STS-LMS, n=61) were treated with doxorubicin 60 mg/m² and trabectedin 1.1 g/m² in 3 hours every 3 weeks up to six cycles. High ORRs were found: 59.6% for u-LMS and 39.4% for STS-LMS. The most common grade 3–4 treatment-associated adverse events were (febrile) neutropenia, thrombocytopenia, anemia, increased ALT, and fatigue.

The combination of doxorubicin and trabectedin seems promising. The high ORR suggests a potential role in a neoadjuvant setting. So far, only one study on single-agent trabectedin in the neoadjuvant setting for myxoid liposarcoma has been published, reporting a response rate of 24%. Another point of interest would be the continuation of trabectedin after the six cycles of combined trabectedin and doxorubicin since a very recent study of Le Cesne et al found that continued trabectedin in patients with disease control after six cycles is superior to restarting treatment at progression.

The combination of trabectedin and gemcitabine has proven to be not tolerable. A Phase Ib trial in pretreated STS patients treated with a combination of trabectedin and olaparib, a PARP inhibitor, is now open for recruitment (NCT02398058).

**Conclusion**

In conclusion, trabectedin has consistent activity in all types of STS. Trabectedin can be positioned after failure of first-line therapy with anthracyclines or in patients unfit for anthracycline-based therapy. There is no rationale to replace anthracycline-based first-line therapy with trabectedin currently, since trabectedin has not demonstrated a survival or response rate advantage over doxorubicin.

The combination of doxorubicin and trabectedin deserves further study as first-line palliative therapy as well as in the neoadjuvant setting. This is also the case for trabectedin maintenance therapy after induction therapy with six cycles of doxorubicin.

For second-line and further therapy, no preferred sequence suitable for all STS subtypes can be provided. The choice should be made on an individual basis, taking into account the histological subtype, aim of the treatment, and the expected toxicity. Unfortunately, almost no quality-of-life data are available for the different chemotherapeutical options. Future studies should include quality-of-life measurements.

Beyond first-line treatment, trabectedin has the advantage of a relatively favorable toxicity profile, but the disadvantage of the need of a central venous catheter and the 24 hours administration. Based on the expanded access program data, there is more rationale in translocation-related sarcomas for the use of trabectedin in terms of efficacy. In these sarcomas, it seems reasonable to place trabectedin as second-line treatment. In other sarcomas, several options can be considered including trabectedin.

Opportunities for the near future will be the investigation of maintenance therapy with trabectedin after doxorubicin induction therapy and combinations of trabectedin and doxorubicin.

**Disclosure**

WvdG received speaker’s fee from Eli Lilly and Novartis and institutional research grants from Novartis and GSK. RJ has consulted for the following: Pharmamar, JJ, Adaptimmune, Eisai, Daichii Sankyo, Imclone/Lilly, Immodulon, Immunedesign, Merck, and Morphotek. The authors report no other conflicts of interest in this work.

**References**


